Cell proliferation assays revealed that EGFR overexpression or miR-338-3p inhibition increased breast cancer cell growth, while EYA2 knockdown decreased breast cancer cell growth (Supplementary Figure S5A). The gene discussed is EGFR; the disease is breast carcinoma.